Zacks Research Research Analysts Lift Earnings Estimates for Danaher Co. (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Analysts at Zacks Research raised their Q3 2025 EPS estimates for shares of Danaher in a research note issued to investors on Monday, May 20th. Zacks Research analyst R. Department now anticipates that the conglomerate will earn $2.05 per share for the quarter, up from their prior forecast of $2.04. The consensus estimate for Danaher’s current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher’s FY2025 earnings at $8.48 EPS.

Several other research firms also recently weighed in on DHR. Raymond James boosted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Citigroup boosted their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. TD Cowen increased their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Finally, Bank of America lifted their price objective on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Danaher Stock Up 0.3 %

Shares of NYSE:DHR opened at $267.33 on Wednesday. Danaher has a 12-month low of $182.09 and a 12-month high of $268.98. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The firm has a market cap of $198.01 billion, a PE ratio of 45.31, a price-to-earnings-growth ratio of 4.11 and a beta of 0.83. The company has a fifty day simple moving average of $249.54 and a 200 day simple moving average of $238.04.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the business posted $2.36 earnings per share. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BigSur Wealth Management LLC increased its position in shares of Danaher by 87.9% in the first quarter. BigSur Wealth Management LLC now owns 11,540 shares of the conglomerate’s stock worth $2,885,000 after acquiring an additional 5,400 shares in the last quarter. Atria Investments Inc lifted its holdings in shares of Danaher by 4.5% in the first quarter. Atria Investments Inc now owns 41,301 shares of the conglomerate’s stock valued at $10,311,000 after purchasing an additional 1,768 shares in the last quarter. Swedbank AB acquired a new stake in shares of Danaher in the first quarter worth $676,545,000. LRI Investments LLC acquired a new stake in shares of Danaher in the first quarter worth $170,000. Finally, Arrow Financial Corp grew its holdings in shares of Danaher by 1.7% during the first quarter. Arrow Financial Corp now owns 12,792 shares of the conglomerate’s stock valued at $3,194,000 after buying an additional 217 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 172,540 shares of company stock valued at $43,523,481. Company insiders own 10.90% of the company’s stock.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.